@article {117525,
	title = {Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study.},
	journal = {European journal of haematology},
	volume = {87},
	year = {2011},
	month = {2011 Oct},
	pages = {349-54},
	abstract = {<p>This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n = 231). Mean liver iron concentrations (LIC) decreased significantly from 21.1 {\textpm} 8.2 to 14.2 {\textpm} 12.1 mg Fe/g dry weight (dw) at 2 yr (P \&lt; 0.001) in patients with LIC >= 7 mg Fe/g dw at baseline; patients with LIC \&lt; 7 mg Fe/g dw maintained these levels over the treatment period. The proportion of patients with LIC \&lt; 7 mg Fe/g dw increased from 9.4\% at core baseline to 39.3\% by the end of year 2. The results showed that deferasirox enabled therapeutic goals to be achieved, by maintaining LIC in patients with LIC \&lt; 7 mg Fe/g dw at a mean dose of 22.4 {\textpm} 5.2 mg/kg/d and significantly reducing LIC in patients with LIC >= 7 mg Fe/g dw at a mean dose of 25.7 {\textpm} 4.2 mg/kg/d, along with a manageable safety profile.</p>
},
	keywords = {Adolescent, Benzoates, beta-Thalassemia, Body Burden, Child, Child, Preschool, Female, Humans, Iron, Iron Chelating Agents, Male, Prospective Studies, Triazoles},
	issn = {1600-0609},
	doi = {10.1111/j.1600-0609.2011.01661.x},
	author = {Ali Taher and Mohsen S. Elalfy and Kusai Al Zir and Shahina Daar and Abdullah Al Jefri and Dany Habr and Ulrike Kriemler-Krahn and Bernard Roubert and Amal El-Beshlawy}
}
